Tags: 'generic spends a fraction of innovator',
'yet/ a perception innovator exploits',
'lead to steps that 'stifle',
'generics allowed to continue',
'patent grant delayed',
'pre-grant opposition allowed/ any time',
'parallel import permitted: without patentee approval',
High cost of innovation',
'compulsory license issued',
'reasonable opportunity to recover R&D cost',
' amended Act: needed a re-look to remove anomalies',
'new chemical entity (NCE)',
'effective patent protection much less'